SecBot SecBot

ONCY

ONCOLYTICS BIOTECH INC
Nasdaq· Pharmaceutical Preparations· CIK 0001129928 Biotech & Drug Discovery
$0.3400 −0.03 (−8.11%)
Nov 16 4:00 PM ET · prev $0.3700
Market cap
$48.8M
Nano cap
Consensus
Buy
75% Buy or better · 8 analysts
Median target
🔒 Subscribers only
1 year
−67.6%
from $1.05 · Nov 17
30 days
−32.0%
from $0.5000
52-week range
$0.3400–1.27
at the low
Avg volume 20D
1.00M
Nov 5 spike 2.86M
Short interest
8.68M
≈6.6% of shares · −3.8%
Days to cover
9.9
at average volume
Insider net
+$258.8K
10 buyers · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Reddit crowd
50°
Neutral · 1 mention this week
SecBot read BULLISH 18 reports · 90 days
Balance 0 bearish · 3 bullish · 15 neutral oldest → newest, height = score
Avg score ·High conf. 9/18

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    10 insiders bought $258.8K at an average $0.8507. No open-market sales. Price is 60% below their cost.

  • InstitutionsMIXED

    Q3 2026: 5 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    6 of 8 rate it Buy or better.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.080 → −$0.085 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −3.8% to 8.68M shares. 9.9 days to cover, ≈6.6% of shares.

  • TrendDOWNTREND

    40% below its 50-day average. New closing low $0.3400 on Nov 16.

  • SocialQUIET

    Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Invesco Ltd.ADD142,242$95.0K
CITIGROUP INCDOUBLED121,462$81.2K
FIFTH THIRD BANCORPADD85,526$57.1K
HRT FINANCIAL LPTRIM37,332$24.0K
UBS Group AGTRIM16,524$11.0K
TD Waterhouse Canada Inc.TRIM453$291.00
NewEdge Advisors, LLCDOUBLED300$200.00
JPMORGAN CHASE & CONEAR_EXIT35$24.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 75% rate it Buy or better
Strong Buy1Buy5Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 19, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 26, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 13, 2026
Contract
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell…
Nov 11, 2026
Contract
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell…
Nov 9, 2026
FDA
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
Nov 4, 2026
FDA
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
Oct 27, 2026
FDA
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
Oncolytics announced durability and survival data in anal cancer from GOBLET study, with 100% of responding patients survived for longer than one…

Insider ledger

Form 4
$258.8K
bought · 10 insiders
$0
sold · 0 insiders
−60.0%
vs their $0.8507 cost
DateInsiderTypeValue
Jun 1, 2026
Brown Deborah Margaret
Director
Jun 1, 2026
AWARD30,000 sh
Jun 1, 2026
Andrews Patricia S
Director
Jun 1, 2026
AWARD30,000 sh
Jun 1, 2026
Holtham Angela
Director
Jun 1, 2026
AWARD30,000 sh
Jun 1, 2026
Glover Stephen C.
Director
Jun 1, 2026
AWARD96,000 sh
Jun 1, 2026
Heineman Thomas Charles
Chief Medical Officer
Jun 1, 2026
AWARD260,000 sh
Jun 1, 2026
Seizinger Bernd R.
Director
Jun 1, 2026
AWARD30,000 sh
Jun 1, 2026
Parsons James T.
Director
Jun 1, 2026
AWARD30,000 sh
Jun 1, 2026
Hagerman Allison
Chief Technology Officer
Jun 1, 2026
AWARD260,000 sh

Earnings setup

Estimates
−$0.08
EPS estimate, this quarter
−6%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.08-$0.09–-$0.08-1.4%$0.00
Next Q-$0.06-$0.07–-$0.06+7.7%$0.00
Current FY-$0.38-$0.39–-$0.37-0.1%$0.00
Next FY-$0.28-$0.28–-$0.23+3.4%$0.00

Washington

Corporate Lobbying

4 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
8,679,124
shares short
-3.8%
vs prior settlement
9.9
days to cover
≈6.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
All social signals and their track records

SecBot reports

25 filings · 7 press releases · 7 bullish · 3 bearish · 15 neutral
All ONCY filing & press-release reports (32)